Expression and significance of IFNAR1 in oral squamous cell carcinoma

doi:10.19438/j.cjoms.2017.03.010

Abstract

Abstract: PURPOSE: To investigate the expression of type I interferon receptor 1(IFNAR1) in oral squamous cell carcinoma (OSCC) and normal mucosa, and to explore its relationship with clinical pathological characteristics and prognosis. METHODS: The expression of IFNAR1 in 108 cases with OSCC and 16 cases with normal oral mucosa was detected by immunohistochemistry. The relationship between the expression of IFNAR1 in OSCC tissues and clinical pathological characteristics were analyzed. The data were analyzed with SPSS17.0 software package. RESULTS: The expression of IFNAR1 in OSCC was significantly higher than that in normal oral mucosa. The expression of IFNAR1 was closely correlated with T stage, cervical lymph node metastasis, TNM stage and pathological differentiation (P<0.05); while gender, age, location, smoking and drinking had no correlation with IFNAR1 (P>0.05). IFNAR1 expression was an important factor to predict prognosis of OSCC patients with HR=1.879(95% CI=0.967-3.651, P=0.063). Patients with higher expression of IFNAR1 had poorer prognosis shown by Log-rank test (P=0.057). CONCLUSIONS: The expression of IFNAR1 in OSCC was significantly higher than that in normal oral mucosa, and it is a potential risk factor for OSCC. It has a tendency to be related to the prognosis of OSCC patients. IFNAR1 expression in tumor tissues can be a surrogate to select patients who can benefit from interferon alpha treatment in OSCC.

Key words: IFNAR1, Immunohistochemistry, Oral squamous cell carcinoma

CLC Number:

R739.8

ZHU Li-lin, YANG Wen-yi, MA Hai-long, HU Jing-zhou.. Expression and significance of IFNAR1 in oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2017, 15(3): 240-244.

References

[1] Rivera C. Essentials of oral cancer [J]. Int J Clin Exp Pathol, 2015, 8(9): 11884-11894.
[2] Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer [J]. Oral Oncol, 2009, 45(4-5): 309-316.
[3] Zhang SK, Zheng R, Chen Q, et al. Oral cancer incidence and mortality in China, 2011 [J]. Chin J Cancer Res, 2015, 27(1):44-51.
[4] Chill JH, Quadt SR, Levy R, et al. The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding [J]. Structure, 2003, 11(7): 791-802.
[5] Takaoka A, Yanai H. Interferon signalling network in innate defence [J]. Cell Microbiol, 2006, 8(6): 907-922.
[6] de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions [J]. J Biol Chem, 2007, 282(28): 20053-20057.
[7] Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy [J]. J Interferon Cytokine Res, 2011, 31(7): 545-552.
[8] Wagner TC, Velichko S, Chesney SK, et al. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors [J]. Int J Cancer, 2004, 111(1): 32-42.
[9] Booy S, Hofland LJ, Waaijers AM, et al. Type I interferon receptor expression in human pancreatic and periampullary cancer tissue [J]. Pancreas, 2015, 44(1): 99-105.
[10] Kamai T, Yanai Y, Arai K, et al. Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasis [J]. BMC Cancer, 2007, 7: 159.
[11] Chang LC, Fan CW, Tseng WK, et al. IFNAR1 is a predictor for overall survival in colorectal cancer and its mRNA expression correlated with IRF7 but not TLR9 [J]. Medicine(Baltimore), 2014, 93(29): e349.
[12] Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy [J]. Nat Rev Cance, 2016, 16(3): 131-144.
[13] Wu CF, Andzinski L, Kasnitz N, et al. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung [J]. Int J Cancer, 2015, 137(4): 837-847.
[14] Bhattacharya S, HuangFu WC, Dong G, et al. Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses [J]. Oncogene, 2013, 32(36): 4214-4221.

[1]	CHEN Hua, LI Jing, LUO Mei. Effect of salidroside on the growth of oral squamous cell carcinoma cells through regulating NRF2/KEAP1 pathway [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(5): 424-429.
[2]	HUANG Can, LUO Tao, SUN Yu. The predictive value of modified frailty assessment tool for postoperative complications in elderly patients undergoing flap reconstruction with oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(4): 373-377.
[3]	SUN Xiao-mei, DUAN Xiao-feng. Research progress of deubiquitinase in oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(3): 294-299.
[4]	LI Jin-cun, ZHAI Kun, HU Chen, LIU Xu-ying, MA Xing-ping, MA Jian. Integration of WGNCA and PPI networks to identify key genes for oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(2): 128-136.
[5]	ZHOU Xin-xia, LIU Jing-hao, GAN Gui-fang, CHEN Fu-xiang. The expression and biological functions of sphingosine-1-phosphate receptor 4 in oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(1): 10-15.
[6]	LI Hua-sheng, ZHOU Di, HAN Nan-nan, YAN Ming, RUAN Min. Lycorine suppressed oral squamous cell carcinoma cell proliferation and invasion via scap protein degradation: an experimental study [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(1): 29-35.
[7]	HAN Lin-zi, ZHOU Jian-hua, DONG lei, ZHAO Lu, YUAN Rong-tao. Research progress on the effect of cancer-associated fibroblasts on biological behavior of oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(1): 84-91.
[8]	LIU Heng, LI Yong-di, YIN Xin-hai, DUAN Xiao-feng. Expression of ferritin heavy chain 1 in head and neck squamous cell carcinoma and its effect on proliferation, migration and invasion of oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(6): 529-537.
[9]	ZHAO Tong-chao, LIANG Si-yuan, ZHOU Zhi-hang, ZHU Fang-xing, JU Wu-tong, TAN Yi-ran, LIU Ying, ZHONG Lai-ping. Correlation between BMI and prognosis and induction chemotherapy in patients with locally advanced oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(6): 559-565.
[10]	ZHU Fang-xing, ZHOU Zhi-hang, JU Wu-tong, TAN Yi-ran, LIU Ying, ZHONG Lai-ping, ZHAO Tong-chao. Baseline derived neutrophil to lymphocyte ratio predicting the prognosis of local advanced oral squamous cell carcinoma: a retrospective study over 10 years [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(6): 566-571.
[11]	JIN Neng-hao, TIAN Yu, ZHU Liang, QIAO Bo, LI Liang-bo, ZHANG Hai-zhong, ZHANG Lei. Clinical significance of PD-L1 and tumor immune microenvironment in predicting neoadjuvant therapy for oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(6): 572-578.
[12]	LI Gui-zhong, LI Jie-ying, ZHOU Kai, MENG Yu-xiang, WANG Ke-xin, GE Sheng-you, SONG Kai, FENG Yuan-yong, TAO Yue-qin, ZHAN Xiao-hong, SHANG Wei. Effect of extranodal extension on TNM staging and survival in patients with oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(4): 377-383.
[13]	SI Cheng-yun, LIU Meng-qiu, WENG Hai-yan, ZHANG Li-yu, AN Xing-fei, ZHOU Yu. Accuracy of MRI to measure and evaluate clinical staging of oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(4): 390-396.
[14]	WU Zhu-hao, ZHANG Xing-wei, SUN Ya-wei, LI Zi-hui, CHEN Xin, PU Yu-mei, HU Qin-gang, DONG Ying-chun, SUN Guo-wen. Application of ICG fluorescence navigation during salvage surgery for advanced oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(3): 248-252.
[15]	REZIWANGULI·Yasen, MAIREPATI·Maiming, LI Chen-xi, GONG Zhong-cheng. Research progress in the role and mechanism of Porphyromonas gingivalis in promoting oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(2): 186-190.